The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people aged 12 and older. Ebglyss targets inflammation, providing significant skin clearance and itch relief.

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The medication is for adults and children 12 and older. In studies, people saw significant skin clearance in as little as four weeks and meaningful itch relief as early as two weeks.

The U.S. Food and Drug Administration has approved Elanco Animal Health's dermatitis treatment for dogs, the health regulator's website showed on Thursday.